Introducing the world’s only searchable, sortable database of RMAT Designations that is continuously updated on a daily basis.
Congress included several provisions related to cell and gene therapies in the 21st Century Cures Act, the most important of which is the RMAT (“Regenerative Medicine Advanced Therapy”) Designation.
Sponsors of cell and gene therapies may be eligible to obtain an RMAT designation if the product is intended to treat serious or life-threatening diseases and if there is preliminary clinical evidence that it could address unmet medical needs.
As of 2019, dozens of companies have been issued RMAT designations for a range of regenerative medicine products, including cell therapies, gene therapies, and tissue engineering applications.
Take the time and effort out of tracking FDA approvals of RMAT designations by utilizing this searchable, sortable database that is continuously updated by BioInformant’s dedicated team of analysts.
This comprehensive database includes:
- Company Name
- Product Name
- Medical Indication
- Date of Approval
- Product Category (Cell Therapy, Gene Therapy, Tissue or Combination Product)
- Company Website
- Link to RMAT Announcement
Claim the RMAT Database
Because this database is an essential resource within our company, we are confident it will be a valuable resource for you too.
It was originally developed in-house for our own purposes, but we have had more and more clients requesting access to it.
For this reason, we updated and expanded it with additional company details. Now, we have launched it for the public – for a limited-time only.
Your product will be delivered instantly as an Excel download.
Plus, you will get 12-months of FREE updates so you can effortlessly stay up-to-date. Request one at anytime by emailing [email protected]
Of course, your investment is backed by a Greater than 100% Money Back Guarantee.